

UCSF

UC San Francisco Previously Published Works

Title

Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials.

Permalink

<https://escholarship.org/uc/item/2ns8j05t>

Journal

Critical Care, 28(1)

Authors

Bagshaw, Sean
Bhatraju, Pavan
Bihorac, Azra
et al.

Publication Date

2024-03-21

DOI

10.1186/s13054-024-04877-4

Peer reviewed

REVIEW

Open Access



Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials

Matthieu Legrand^{1*}, Sean M. Bagshaw², Pavan K. Bhatraju^{3,4}, Azra Bihorac^{5,6}, Ellen Caniglia⁷, Ashish K. Khanna^{10,8,9}, John A. Kellum¹¹, Jay Koyner¹², Michael O. Harhay¹³, Fernando G. Zampieri², Alexander Zarbock¹⁴, Kevin Chung¹⁵, Kathleen Liu¹⁶, Ravindra Mehta¹⁷, Peter Pickkers¹⁸, Abigail Ryan¹⁹, Juliane Bernholz²⁰, Laura Dember²¹, Martin Gallagher²², Patrick Rossignol^{23,24,25} and Marlies Ostermann²⁶

Abstract

Acute kidney injury (AKI) often complicates sepsis and is associated with high morbidity and mortality. In recent years, several important clinical trials have improved our understanding of sepsis-associated AKI (SA-AKI) and impacted clinical care. Advances in sub-phenotyping of sepsis and AKI and clinical trial design offer unprecedented opportunities to fill gaps in knowledge and generate better evidence for improving the outcome of critically ill patients with SA-AKI. In this manuscript, we review the recent literature of clinical trials in sepsis with focus on studies that explore SA-AKI as a primary or secondary outcome. We discuss lessons learned and potential opportunities to improve the design of clinical trials and generate actionable evidence in future research. We specifically discuss the role of enrichment strategies to target populations that are most likely to derive benefit and the importance of patient-centered clinical trial endpoints and appropriate trial designs with the aim to provide guidance in designing future trials.

Introduction

Acute kidney injury (AKI) is associated with serious short- and long-term complications [1]. Critically ill patients with severe AKI [defined as Kidney Disease: Improving Global Outcomes (KDIGO) AKI Stage 2 or 3] have an in-hospital mortality greater than 25% which exceeds 50% when renal replacement therapy (RRT) is needed. In the PROCESS study, 60-day hospital mortality was 6.2% for patients without AKI, 16.8% for those with stage 1 and 27.7% for patients with AKI stage 2 or 3 [2, 3]. Patients with less severe AKI, including subclinical AKI [defined as early kidney damage identified by biomarkers without serum creatinine (SCr) rise] are also at risk

of both short- and long-term complications, including incident or worsening chronic kidney disease (CKD) and major adverse cardiovascular events (MACE) [4–6].

Sepsis is the most common contributing factor to AKI in acutely and critically ill patients [7]. Our understanding of the pathophysiology of sepsis-associated AKI (SA-AKI) has improved over the last few years and promising therapeutic targets are emerging [8], giving hope to improved clinical outcomes. The 2023 Kidney Disease Clinical Trialists (KDCT) workshop, held in Washington D.C. (USA) in March 2023, provided multiple stakeholders, including clinical researchers, regulatory authorities and commercial partners, with a scientific forum to discuss the current state of SA-AKI clinical research, identify challenges and priorities, and propose strategies for future research toward precision medicine (Table 1) [9]. The scientific program was developed by the KDCT scientific academic committee and focused predominantly

*Correspondence: Matthieu Legrand
Matthieu.Legrand@ucsf.edu
Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 1 Description of the terminology used in precision medicine, adapted from Seymour et al. [64] and Stanski et al. [65]

Term	Description
Phenotype	Clinical features or traits that characterize a group of patients within a disease or syndrome, including genetics, environmental factors and other clinically observed characteristics
Endotype	Subset of patients defined by distinct biological mechanism of disease within a phenotype
Sub-phenotype	A subset of clinical features in patients with a shared phenotype that distinguishes the group from other groups within that phenotype
Prognostic	Indicators used to inform about risks of various outcomes
Predictive	Indicators providing information about the likelihood of response to a given treatment
Drug (or intervention) response	Differential responses to drug (or intervention) based on phenotype defined by an indicator
Heterogeneity of treatment effects (HTE)	Differences in treatment responses in a group due to variability in drug response phenotype within that group
Treatable trait	A subgroup characteristic that can be successfully targeted by an intervention
Enrichment	A prospective strategy for addressing HTE by reducing heterogeneity of the sample population or increasing representation of patients with similar risk profiles

on the role of sub-phenotyping, enrichment strategies, selection of appropriate endpoints and outcomes, and consideration of alternative trial designs. This narrative review summarizes the presentations, discussions and conclusions of the meeting but does not include a systematic review of the existing literature.

Why should SA-AKI be considered a specific entity?

The reported occurrence rate of SA-AKI varies between 25 and 75% depending on the patient cohort, type and severity of sepsis, and criteria used to define the condition [8]. The prognosis is variable but current data suggests that SA-AKI is associated with a higher risk of mortality and a lower chance of renal recovery than other types of AKI.

In 2022, an international Acute Disease Quality Initiative (ADQI) consensus meeting focused on the definition, epidemiology and management of SA-AKI [8]. The expert panel acknowledged that SA-AKI was a heterogeneous syndrome that occurs as a direct consequence of sepsis (i.e., sepsis-induced AKI) or as a result of indirect mechanisms driven by interventions for sepsis or, in rare cases, because of factors not directly related to sepsis but nevertheless occurring in these patients. In the absence of an accepted definition of SA-AKI, the panel proposed to define SA-AKI by the presence of both, sepsis (as per Sepsis-3 criteria) and AKI (as defined by the KDIGO criteria). Further, sepsis-induced AKI was considered a sub-phenotype of SA-AKI in which sepsis-induced mechanisms directly lead to kidney damage.

The understanding of the pathophysiology of SA-AKI has significantly improved thanks to advances in experimental model design and analytical techniques. Several specific processes and mechanisms have been identified that may contribute to the development of glomerular

dysfunction and/or tubular injury in sepsis [7, 10]. These include endothelial dysfunction, inflammation, alteration of the renal microcirculation, activation of the renin–angiotensin–aldosterone system (RAAS), mitochondrial dysfunction, complement activation, direct tubular injury and metabolic reprogramming [11]. While an in-depth review of the pathophysiology of SA-AKI is beyond the scope of this review, a few key processes believed to be important contributors are listed as they may be targets for therapeutic interventions (Fig. 1).

Role of biomarkers for sub-phenotyping and enrichment

The application of various different biomarkers has provided granularity to the syndrome of AKI and allowed the identification of sub-phenotypes with different etiologies, pathophysiological mechanisms and outcomes. One of the benefits is the opportunity for prognostic and predictive enrichment in clinical trials. Prognostic enrichment describes the application of a biomarker to identify a cohort of patients that is at high risk for a specific outcome (e.g., severe persistent AKI, advanced CKD, mortality), whereas predictive enrichment aims to identify patients who are likely to respond in a similar way to a specific treatment, usually because they share a common underlying pathobiology [12].

Prognostic enrichment sub-phenotyping

Identifying SA-AKI sub-phenotypes with a higher risk of poor outcome provides opportunities to target interventions toward the higher risk group and to exclude cohorts that may not benefit or potentially come to harm. Two recent studies by Ozrazgat-Baslanti et al. tracked the clinical trajectories of AKI, one for surgical patients and one for all hospitalized patients with AKI [13, 14]. For




Fig. 1 Areas identified as potential candidates to improve sepsis-associated AKI outcomes and to be considered as priorities for testing in clinical trials

surgical patients, the ADQI criteria were used to differentiate between ‘No AKI,’ ‘Rapidly Reversed AKI,’ ‘Persistent AKI with Renal Recovery,’ and ‘Persistent AKI without Renal Recovery’ [14]. Surgical patients with sepsis who exhibited ‘Persistent AKI without Renal Recovery’ had the highest hospital mortality (45%), RRT use (40%) and decline of glomerular filtration rate (GFR) in the year following surgery. Among hospitalized patients, those with ‘Persistent AKI without Renal Recovery’ also had the highest hospital mortality (28%), need for RRT (13%) and risk of death within one year of discharge (19%). For clinicians and researchers, the challenge is to identify these at-risk patients early and to investigate potential interventions that may modify any of the outcomes.

Among patients included in the FROG-ICU and ADRENOSS study, the authors showed that an elevated proenkephalin level > 80 pmol/L (found in roughly 6% of the cohorts) at the time of admission to the Intensive Care Unit (ICU) without meeting the serum creatinine (SCr) or urine output criteria of AKI, was associated with an increased risk of mortality [15, 16]. In a planned sub-study of the PROCESS trial (a randomized controlled trial exploring the role of early goal directed therapy), the authors measured urinary cell cycle arrest markers tissue inhibitor of metalloproteinases 2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) before

and after the 6-hour resuscitation period [17, 18]. They demonstrated that patients who still had an elevated biomarker level ($[TIMP-2] \cdot [IGFBP7] > 0.3$) after receiving fluid resuscitation were at higher risk for a composite endpoint of progression to severe AKI (Stage 2/3), receipt of dialysis or mortality. The incidence of this composite endpoint was similar in patients with elevated biomarkers post-resuscitation regardless of their pre-resuscitation biomarker status and also similar in those with and without AKI at enrollment based on SCr and urine output criteria.

Accurate sub-phenotyping based on clinical features will be essential to making full use of the large-scale electronic health record (EHR) data to understand and manage AKI. Confusion can result from existing efforts to define sepsis subclasses, where researchers used different approaches for classification (empirical, hypothesis-based or agnostic) and interchangeable terms (such as subgroup, sub-phenotype or endotype) that were not reconciled with terminology applied in previously published studies [19]. Recent studies in unsupervised machine learning (ML) have given promise to the prospect of classifying AKI patients into sub-phenotypes. These ML models characterize sub-phenotypes without adhering to any preconceived hypothesis or guidelines. Three published studies separately developed ML models

to sub-phenotype adult ICU patients with AKI [20–22], adult ICU patients with SA-AKI within 48 h of admission and hospitalized adults with AKI within 48 h of admission. Two studies identified biomarkers that were significantly different between sub-phenotypes, and all studies were able to differentiate sub-phenotypes related to decreased renal function and higher mortality [20, 21, 23]. Finally, AKI trajectories have been proposed to define different phenotypes. The ADQI group published consensus statements regarding the definitions of ‘SA-AKI’ and its timing (‘early SA-AKI,’ within 48 h of diagnosis of sepsis and ‘late SA-AKI,’ defined as AKI between 48 h to day 7 after sepsis diagnosis) and also adopted the previously proposed timelines for AKI (7 days or less), acute kidney disease (1–90 days) and chronic kidney disease (90+ days) [8].

A major challenge is the fact that current methods for data-driven phenotyping are heterogeneous, there are no reproducible approaches across differing methodologies and datasets to identify sub-phenotypes and endotypes, and resources to aggregate the existing strategies for clinical impact are lacking [24]. These models were developed in specific cohorts and settings and their generalizability remains uncertain across different health systems and critical care units. Confirmatory studies in diverse settings will be needed. Any proposed sub-phenotypes should be assessed by testing for (1) consistency and reproducibility in other datasets, (2) biological plausibility and (3) clinical utility (i.e., ability to identify patients at high risk for a specific outcome or to predict treatment response). Finally, the ideal phenotyping algorithm should impact clinical decision making in real time and provide increased value over current severity scores.

Predictive enrichment sub-phenotyping

Because of the heterogeneous nature of critical illness, many clinical studies have not been able to identify treatment benefits. The goal of precision medicine is to match the best available treatment option with the specific patient populations. Developing a classification system for biomarker-driven AKI endotypes will improve the understanding of AKI and enable researchers to engage in more specific therapeutic trials, thus getting closer to the goal of providing precision medicine to patients with AKI [24, 25] (Fig. 2).

In the setting of SA-AKI, an appealing approach is using big data to identify cohorts with shared biology (i.e., comorbidities, laboratory results, clinical variables, biomarkers) [16, 18]. Several groups have used artificial intelligence and advanced ML methods to find a variety of signals in the wealth of available data.

In the FINN-AKI cohort, investigators applied latent class analysis (LCA) and differentiated between two

endotypes of AKI in patients with sepsis [21]. Patients with endotype-2, defined by higher plasma levels of inflammatory and endothelial injury markers, had higher 90-day mortality compared to endotype-1 (41% vs 29%) and also a lower probability of short-term renal recovery.

In a retrospective analysis of two ICU cohorts, Bhatraju and colleagues used LCA to characterize two distinct SA-AKI endotypes [26]. All patients had plasma collected within 48 h of ICU admission; 29 different clinical and laboratory values and seven vascular host and inflammatory biomarkers were included in the analysis. Different levels of specific biomarkers (including angiotensin 1 and 2) and significant differences in the incidence of certain single-nucleotide polymorphism (SNPs) within angiotensin-2 were identified across the 2 endotypes. A two-group model best separated the data with approximately 60% of patients in endotype-1 and 40% in endotype-2 category. These findings were replicated in a validation cohort where endotype-2 was associated with a 2 or more greater risk of renal non-recovery and 28-day mortality compared to endotype-1, even after adjusting for severity of illness.

The authors then developed a parsimonious prediction model that included the ratio of angiotensin-2/1 and soluble tumor necrosis factor receptor-1 (sTNFR-1). The model had fairly good c-statistic to predict AKI sub-phenotypes; patients with lower biomarkers of endothelial dysfunction and inflammation were characterized as endotype-1. When applying the model to the VASST database (vasopressin versus norepinephrine in patients with septic shock), the authors observed that these two AKI endotypes identified prior to randomization showed heterogeneity of treatment effect for the early addition of vasopressin to norepinephrine [26]. Specifically, patients classified as endotype-1 had a lower 90-day mortality with the early addition of vasopressin, while mortality was not significantly different in the endotype-2 group if randomized to vasopressin. Further research is necessary to test these endotypes in prospective trials in SA-AKI. Of note, these sub-phenotypes share characteristics with other sub-phenotypes reported in other conditions such as acute respiratory distress syndrome (ARDS) [27]. This observation may not be surprising given that (i) the mechanisms of sepsis-induced organ failure are likely (at least partially) shared between organs, and (ii) similar biomarkers were used to identify sub-phenotypes. In this line, sepsis is the leading cause of ARDS and sub-phenotypes were replicated between sepsis and ARDS [28].

Seymour and colleagues harnessed data from four distinct sepsis cohorts (over 40,000 patients) to develop and validate four distinct phenotypes of sepsis [29]. They demonstrated differences in the incidence of organ injury (AKI, liver failure), as well as differences in biomarkers




Fig. 2 Visual representation of sub-phenotypes (classifying patients based on clinical and physiological characteristics), endotypes (classifying patients based on mechanistic pathways underlying the phenotypes) and treatable traits that would lead to targeted therapies to be tested in randomized trials. Of note, overlap can exist between different phenotypes, endotypes and treatable traits

(inflammatory, coagulopathy, etc.) between sub-phenotypes with cross-variation in sub-phenotypes within trials and the differential treatment effects. These studies suggest that heterogeneity of treatment effect exists across sub-phenotypes and that so-called 'negative' therapies may be reconsidered in enriched SA-AKI populations and among specific sub-phenotypes.

Predictive enrichment in randomized clinical trials

Most AKI sub-phenotypes were discovered or validated retrospectively using existing databases. In only a few prospective studies and clinical trials, biomarker-based sub-phenotyping was implemented for predictive enrichment. The EUPHRATES trial was an interventional RCT where a biomarker (endotoxin activity) was used to risk stratify patients for enrollment, regardless of AKI status. Patients with an endotoxin activity of 0.6 or higher were randomized to receive two hemoadsorption treatments using polymyxin B and usual care versus sham hemo-perfusion and usual care [30]. There was no difference

in 28-day mortality between both groups. However, a subgroup analysis identified a 'sweet spot' of endotoxin activity (between 0.6 and 0.9) where patients may derive a benefit from hemoadsorption [31]. The trial did not include an assessment of the response to therapy and the protocol had no customization to patients' response. It could be argued that some patients may have benefitted from greater customization of therapy.

A new trial, Tigris (NCT03901807), is currently underway to test this hypothesis prospectively. Importantly, the statistical analysis plan describes combining Tigris and EUPHRATES data using Bayesian statistics [32]. This approach is similar in concept to adaptive clinical trials which drop certain arms or groups as the trial progresses or even add or eliminate interventions. These adaptations incur less penalty when planned prospectively and may be important tools for future studies in SA-AKI.

In the ATHOS-3 trial [33], patients with vasodilatory shock on high-dose vasopressors were randomized to receive synthetic Angiotensin II or placebo with

continuation of other vasopressors. The trial demonstrated that about 70% of patients in the intervention arm met the primary endpoint of a mean arterial pressure (MAP) >75 mmHg or increase by 10 mmHg or more from baseline within 3 h of drug initiation. While the phase III trial did not show a mortality difference, subsequent work in specific subgroups suggested a survival benefit, including those with septic AKI and patients in whom Angiotensin II was introduced at lower doses of vasopressors [34, 35].

Healthy volunteers have low levels of angiotensin I and angiotensin II and a low angiotensin I/II ratio. In contrast, some patients with vasodilatory shock have very high levels of angiotensin I with a significantly elevated angiotensin I/II ratio, suggesting reduced conversion of angiotensin I to angiotensin II, resulting in angiotensin II deficiency. Patients with a substantially elevated Ang I/Ang II ratio, who were randomized to receiving exogenous Angiotensin II, had a survival benefit compared to the group that received placebo [36]. In a post hoc analysis of the ATHOS-3 trial, the authors measured angiotensin I and renin levels over time (at study initiation and 3 h later) and demonstrated that the angiotensin I and renin concentrations did not decrease in patients who received placebo while the levels fell in those who were randomized to angiotensin II therapy [37]. Based on this finding, the authors hypothesized that the activity of the angiotensin converting enzyme (ACE) was reduced in patients with septic shock and/or endothelial dysfunction [38]. Giving angiotensin II to a subgroup of septic patients with hyperreninemia enrolled in the ATHOS-3 trial was associated with lower mortality. ACE is largely a pulmonary capillary endothelial enzyme, the activity of which decreases with increase in severity of lung injury. It is similarly proposed to decrease in those with other reasons associated with altered pulmonary blood flow, such as cardiac surgical patients or patients on extracorporeal membrane oxygenation (ECMO) [39]. ACE activity is difficult to measure. However, reduced ACE activity usually results in increased renin release and potential diversion of the RAAS pathway through ACE 2, leading to more Ang 1–7 than Ang II [40, 41]. Thus, renin can be considered a surrogate marker of ACE activity. However, a true point of care bedside renin assay to target therapy is lacking and further work to define the role of biomarkers of the RAAS for predictive enrichment to guide Angiotensin II administration is needed. Finally, these post hoc analyses highlight the overlap between sub-phenotypes, have a relative small sample size with a risk of type 1 error and should be considered exploratory (Table 2).

Which endpoint for SA-AKI clinical trials?

Clinical trials in critical care, and particularly in critical care nephrology, have traditionally focused on endpoints believed to be of clinical importance such as kidney recovery (i.e., progression to end-stage kidney disease [ESKD] or non-recovery from AKI) [42, 43]. The risk of death is high in critically ill patients, particularly in those with sepsis and multi-organ dysfunction including AKI, approaching 40–50%. For approval of new drugs, regulatory authorities currently favor endpoints such as all-cause mortality or ‘Major adverse kidney event’ (MAKE), a composite of all-cause mortality or receipt of dialysis or significant decline in kidney function [44, 45]. However, death is also an important competing endpoint of renal recovery and may be affected by many other factors than AKI. Even though MAKE considers the competing risk of death with recovery from AKI, the attributable mortality of AKI and non-recovery from AKI is uncertain and a substantial fraction of death may not be related to kidney events. Recovery from AKI is another important endpoint [46]. Non-recovery from AKI is associated with higher mortality and morbidity, including a risk for chronic kidney disease. However, assessing recovery solely using serum creatinine can be misleading in sepsis given the decrease production and increase volume of distribution that may overestimate the renal function. Alternative biomarkers and measuring glomerular filtration rate (i.e., iohexol clearance) may better fit the purpose.

Although not specific to SA-AKI, additional endpoints have been proposed that may also better reflect patient and family perceptions of their experience and outcomes after critical illness [47–49]. These include endpoints representing preservation (or improvement) of their function [e.g., physical function; activities of daily living (ADL), instrumental activities of daily living (IADL)], mental health, cognitive function or health-related quality-of-life (HRQOL) [50].

How these endpoints rank in terms of importance to patients and their families is not certain and will need to be explored. Critical illness, major adverse kidney events, chronic kidney failure and longer-term RRT are certainly associated with impaired HRQOL but patients’ preferences differ depending on their personal views, sociocultural impact and circumstances (Fig. 3) [51–53].

Clinical trials have generally not routinely integrated a wider spectrum of survivorship endpoints that may have great (or even greater relative) importance to patients (i.e., disability; return to home, social function; return to work) and their families (e.g., caregiver burden). Ability to return home, number of days at home, freedom from dialysis and hospital-free days were proposed as potential

Table 2 Examples of different sub-phenotypes derived from post hoc analyses of a randomized controlled trial (Angiotensin II for the Treatment of High-Output Shock-ATHOS-3-trial) [33]

First author (year)	Sub-phenotype 1	Sub-phenotype 2	Main results	Baseline NED
Wieruszewski et al. [34] 3/18/2024 5:35:00 PM	Low NED (≤ 0.25 $\mu\text{g}/\text{kg}/\text{min}$) at baseline, $n = 104$	High NED (> 0.25 $\mu\text{g}/\text{kg}/\text{min}$), $n = 217$	In patients receiving low NED at randomization, administration of AT II was associated with lower 28-day mortality (HR 0.509; 95% CI 0.274–0.945, $p = 0.03$), while no difference was observed in the high-NED subgroup (HR 0.933; 95% CI 0.644–1.350, $p = 0.71$)	0.21 (0.18–0.23) $\mu\text{g}/\text{kg}/\text{min}$ in the low-NED group vs 0.47 (0.33–0.68) $\mu\text{g}/\text{kg}/\text{min}$ in the high-NED group for patients in the AT II group
Bellomo et al. [37]	Low serum renin concentrations at baseline (below median), $n = 127$	High serum renin concentrations at randomization (above median), $n = 128$	In patients with high renin concentrations, treatment with AT II was associated with lower 28-day mortality (50.9%) compared to placebo (69.9%; unstratified hazard ratio, 0.56; 95% confidence interval, 0.35 to 0.88; $p = 0.012$)	0.36 (0.23–0.50) $\mu\text{g}/\text{kg}/\text{min}$ in the high renin group treated with AT-2 vs 0.40 (0.29–0.69) $\mu\text{g}/\text{kg}/\text{min}$ in the placebo group
Ham et al. [66]	Patients requiring ≤ 5 ng/kg/min angiotensin II at 30 min	Patients receiving > 5 ng/kg/min angiotensin II at 30 min	Day 28 survival was higher in the ≤ 5 ng/kg/min subgroup versus the > 5 ng/kg/min subgroup (59% vs 33%, respectively; hazard ratio, 0.48 [95% CI 0.28–0.72], $p = 0.0007$)	0.52 (0.301) $\mu\text{g}/\text{kg}/\text{min}$ (SD) in the low dose vs 0.45 (0.377) $\mu\text{g}/\text{kg}/\text{min}$ (SD) in the high-dose group
Tumlin et al. [35]	Patient receiving RRT at study drug initiation ($n = 45$ AT II, $n = 60$ placebo)	–	In patients receiving RRT at study drug initiation, patients in the AT II group had higher 28-day survival vs placebo (unadjusted HR 0.52; 95% CI 0.30–0.87; $p = 0.012$)	0.46 (0.32–0.78) $\mu\text{g}/\text{kg}/\text{min}$ in the placebo vs 0.36 (0.23–0.49) $\mu\text{g}/\text{kg}/\text{min}$ in the AT II group

In the ATHOS-3 trial, 321 patients with vasodilatory shock receiving high doses of vasopressors (> 0.2 $\mu\text{g}/\text{kg}/\text{min}$ of norepinephrine-equivalent dose) were randomized to receive either angiotensin II or placebo AT II, angiotensin II; HR, hazard ratio; NED, norepinephrine-equivalent dose; RRT, renal replacement therapy; CI, confidence interval




Fig. 3 Visual representation of key outcomes to be considered in clinical trials investigating interventions in sepsis-associated AKI

important patient-centered outcomes for patients suffering from critical illness [49, 54].

Few studies have explored measures of the financial burden of critical illness as endpoints, specifically from the patient and family perspective. Financial challenges after critical illness are commonly experienced, particularly in selected health systems and may derive from medical bills, (e.g., cost for dialysis) changes in insurance coverage, and the loss of employment income [7]. Financial concerns are likely very important outcomes and a source of tremendous stress for patients and their families [55]. Moreover, they may be experienced by families long after the death of their family member.

Innovative clinical trials designs

Beside classic RCT’s with individual patient randomization, more pragmatic designs have gained popularity over the last years [43, 56] (Fig. 4), including in the field of AKI. Designs such as cluster crossover randomized trials have been applied with success in critically ill patients using renal endpoints (i.e., MAKE30) [57, 58]. The cluster crossover design is an efficient approach particularly for trials in which the intervention can be brief and the endpoints occur within a short period of time. The use of EHR to collect data potentially reduces financial costs and also the potential for errors introduced through data entry by research personnel. Most importantly, cluster crossover trials allow the intervention of interest to be embedded into a clinical care workflow which increases the generalizability of the results, supports sustainability of the intervention after the trial and reduces the cost of implementing the trial.

Platform trials allow the testing of multiple interventions and drugs while using a main master protocol, thus gaining efficiency [59]. A successful example is the SMART trial, in which 15,802 adults were randomized to saline or balanced crystalloids using a cluster crossover design. The incidence of MAKE was 14.3% in the balanced fluid group versus 15.4% in the saline group [odds ratio (OR) 0.90; 95% CI 0.82–0.99] [57]. In a secondary analysis of the subgroup of 1641 septic patients, the balanced crystalloids group had a lower 30-day in-hospital mortality compared to the saline group (26.3% vs 31.2%; adjusted OR, 0.74; 95% CI 0.59–0.93), along with a lower incidence of MAKE and a higher number of vasopressor- and RRT-free days compared to the saline group [57].

Another promising area in clinical trial design involves the a priori assessment of heterogeneity in treatment effects (HTE). Clinical trials estimate the average treatment effect on the included sample. As discussed earlier, it is conceivable that different etiologies and sub-phenotypes of AKI or different population (i.e., women vs men) may respond differently to interventions. The assessment of HTE can be made a priori using cluster/phenotypes or proper methods to estimate individualized treatment effects [60]. Assessments of HTE have been suggested to re-assess several completed trials and may be specified a priori to maximize the validity. In a recent report of the effects of ACE inhibitor and angiotensin receptor blocker (ARB) on COVID-19 patients [61], an individualized treatment effect analysis was designed and reported a priori. Patients were randomized to initiation of an ACE inhibitor ($n=257$), ARB ($n=248$), ARB in combination with a chemokine receptor-2 inhibitor ($n=10$) or




Fig. 4 Critical features of an intervention under investigation when designing a more pragmatic or exploratory trial. More pragmatic trials enroll a broader population and tend to increase the generalizability of the trial while more exploratory trials enroll enriched population, at the cost of lower generalizability

no renin-angiotensin-system inhibitor (control; $n = 264$). The investigators estimated the individual-level treatment effect, conditioned on patients' baseline covariates, using machine learning techniques. Expected absolute risk differences were then calculated for conditional average treatment effects at both the individual and subgroup levels. Although no signal of HTE was observed, other trials have succeeded in finding signals of HTE which could, in theory, be useful for guiding both, clinical practice and determining areas for further studies [62, 63]. Explorations of HTE in AKI trials are needed.

Conclusions

SA-AKI is associated with very high mortality and morbidity. Over the last several years, various important clinical trials have improved our understanding of SA-AKI and impacted clinical care. Recent advances in subphenotyping and clinical trial design offer unprecedented opportunities to generate better evidence in these high-risk patients to improve outcomes.

Acknowledgements

SMB is supported by a Canada Research Chair in Critical Care Outcomes and Systems Evaluation.

Author contributions

ML, SB, PKB, AB, EC, AK, JKoy, JKel, FZ and MP wrote the main manuscript text and ML prepared figures. All authors reviewed the manuscript

Funding

No funding was received to write this manuscript.

Availability of data and materials

Not applicable.

Declarations

Ethical approval and consent to participate

Human Ethics and Consent to participate declarations: Not applicable—not IRB approval applies to this review.

Competing interests

SMB has received fees for scientific advisory from Baxter, BioMerieux, BioPorto, Novartis, Sea Star Medical, SphingoTec. SMB is an editor of the journal. RM has received fees for scientific advisory from Baxter, AM Pharma, BioMerieux, Mall-inckrodt, GE Healthcare; Sanofi; Abiomed; NovaBiomed; Novartis; Renasym; Fresenius; and Guard and had received grant support from Fresenius; Fresenius-Kabi. AZ has received fees for scientific advisory from Baxter, SphingoTec, BioMerieux, AM Pharma, Guard Therapeutics, Bayer, Novartis, Renibus, Paion and has received grant support from Fresenius, Baxter and BioMerieux. MO has been awarded research funding from Baxter, BioMerieux, Fresenius Medical and LaJolla Pharma. The funding was received by the institution. LD has received compensation from the National Kidney Foundation for her role as Deputy Editor of the American Journal of Kidney Diseases, consulting fees from AstraZeneca, Cara Therapeutics, and Merck, and compensation for serving on Data and Safety Monitoring Boards for the National Institute of Diabetes and Digestive and Kidney Diseases, and Data Monitoring Committees for CSL Behring and Vertex Pharmaceuticals. JAK is a full-time employee of Spectral Medical and has received consulting fees and grant support from BioMerieux/Astute Medical. KC is an employee of SeaStar Medical. IHS contributed to this manuscript in her personal capacity. The opinions expressed in this paper do not necessarily reflect those of the National Institute of Diabetes, Digestive and Kidney Diseases, the National Institutes of Health, the Department of Health and Human Services, and the government of the USA.

Author details

¹Division of Critical Care Medicine, Department of Anesthesia and Perioperative Care, UCSF, 521 Parnassus Avenue, San Francisco, CA 94143, USA. ²Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton, Canada. ³Division

of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, USA. ⁴Kidney Research Institute, University of Washington, Seattle, USA. ⁵Department of Medicine, University of Florida, Gainesville, FL, USA. ⁶Intelligent Critical Care Center (IC3), University of Florida, Gainesville, FL, USA. ⁷Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA. ⁸Department of Anesthesiology, Section on Critical Care Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA. ⁹Outcomes Research Consortium, Cleveland, OH, USA. ¹⁰Perioperative Outcomes and Informatics Collaborative, Winston-Salem, NC, USA. ¹¹Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA. ¹²University Section of Nephrology, Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, Department of Medicine, University of Chicago, Chicago, IL, USA. ¹³Clinical Trials Methods and Outcomes Lab, Department of Biostatistics, Epidemiology, and Informatics, PAIR (Palliative and Advanced Illness Research) Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ¹⁴Hospital Münster, Münster, Germany. ¹⁵SeaStar Medical, Denver, CO, USA. ¹⁶Divisions of Nephrology and Critical Care Medicine, Departments of Medicine and Anesthesia, University of California San Francisco, San Francisco, CA, USA. ¹⁷Department of Medicine, University of California, San Diego, USA. ¹⁸Intensive Care Medicine, Radboudumc, Nijmegen, The Netherlands. ¹⁹Chronic Care Policy Group, Division of Chronic Care Management, Center for Medicare and Medicaid Services, Center for Medicare, Baltimore, MD, USA. ²⁰AM-Pharma, Stadsplateau 6, 3521 AZ Utrecht, The Netherlands. ²¹Renal-Electrolyte and Hypertension Division, Department of Medicine, Department of Biostatistics, Epidemiology and Informatics, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ²²The George Institute for Global Health, University of New South Wales, Sydney, Australia. ²³FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France. ²⁴INSERM CIC-P 1433, CHRU de Nancy, INSERM U1116, Université de Lorraine, Nancy, France. ²⁵Medicine and Nephrology-Hemodialysis Departments, Monaco Private Hemodialysis Centre, Princess Grace Hospital, Monaco, Monaco. ²⁶Department of Critical Care, King's College London, Guy's & St Thomas' Hospital, London, UK.

Received: 18 November 2023 Accepted: 17 March 2024

Published online: 21 March 2024

References

- Schulman IH, Chan K, Der JS, et al. Readmission and mortality after hospitalization with acute kidney injury. *Am J Kidney Dis.* 2023;S0272-6386(23):00067-77. <https://doi.org/10.1053/j.ajkd.2022.12.008>.
- Angus DC, Barnato AE, Bell D, et al. A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe investigators. *Intensive Care Med.* 2015;41:1549-60. <https://doi.org/10.1007/s00134-015-3822-1>.
- Kellum JA, Chawla LS, Keener C, et al. The effects of alternative resuscitation strategies on acute kidney injury in patients with septic shock. *Am J Respir Crit Care Med.* 2016;193:281-7. <https://doi.org/10.1164/rccm.201505-0995OC>.
- Legrand M, Rossignol P. Cardiovascular consequences of acute kidney injury. *N Engl J Med.* 2020;382:2238-47. <https://doi.org/10.1056/NEJMr a1916393>.
- Chawla LS, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the acute disease quality initiative (ADQI) 16 workgroup. *Nat Rev Nephrol.* 2017;13:241-57. <https://doi.org/10.1038/nrneph.2017.2>.
- Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. *N Engl J Med.* 2014;371:58-66. <https://doi.org/10.1056/NEJMr a1214243>.
- Bellomo R, Kellum JA, Ronco C, et al. Acute kidney injury in sepsis. *Intensive Care Med.* 2017;43:816-28. <https://doi.org/10.1007/s00134-017-4755-7>.
- Zarbock A, Nadim MK, Pickkers P, et al. Sepsis-associated acute kidney injury: consensus report of the 28th acute disease quality initiative workgroup. *Nat Rev Nephrol.* 2023. <https://doi.org/10.1038/s41581-023-00683-3>.
- Zarbock A, Forni LG, Ostermann M, et al. Designing acute kidney injury clinical trials. *Nat Rev Nephrol.* 2024;20:137-46. <https://doi.org/10.1038/s41581-023-00758-1>.
- Doi K, Leelahavanichkul A, Yuen PST, Star RA. Animal models of sepsis and sepsis-induced kidney injury. *J Clin Invest.* 2009;119:2868-78. <https://doi.org/10.1172/JCI39421>.
- Peerapornratana S, Manrique-Caballero CL, Gómez H, Kellum JA. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. *Kidney Int.* 2019;96:1083-99. <https://doi.org/10.1016/j.kint.2019.05.026>.
- Bhavani SV, Semler M, Qian ET, et al. Development and validation of novel sepsis subphenotypes using trajectories of vital signs. *Intensive Care Med.* 2022;48:1582-92. <https://doi.org/10.1007/s00134-022-06890-z>.
- Ozragat-Baslanti T, Loftus TJ, Ren Y, et al. Association of persistent acute kidney injury and renal recovery with mortality in hospitalised patients. *BMJ Health Care Inform.* 2021;28:e100458. <https://doi.org/10.1136/bmjhci-2021-100458>.
- Ozragat-Baslanti T, Loftus TJ, Mohandas R, et al. Clinical trajectories of acute kidney injury in surgical sepsis: a prospective observational study. *Ann Surg.* 2022;275:1184-93. <https://doi.org/10.1097/SLA.0000000000004360>.
- Dépret F, Hollinger A, Cariou A, et al. Incidence and outcome of subclinical acute kidney injury using penkid in critically ill patients. *Am J Respir Crit Care Med.* 2020;202:822-9. <https://doi.org/10.1164/rccm.201910-1950OC>.
- Hollinger A, Wittebole X, François B, et al. Proenkephalin A 119-159 (Penkid) is an early biomarker of septic acute kidney injury: the kidney in sepsis and septic shock (Kid-SSS) study. *Kidney Int Rep.* 2018;3:1424-33. <https://doi.org/10.1016/j.ekir.2018.08.006>.
- Molinari L, Del Rio-Pertuz G, Smith A, et al. Utility of biomarkers for sepsis-associated acute kidney injury staging. *JAMA Netw Open.* 2022;5:e2212709. <https://doi.org/10.1001/jamanetworkopen.2022.12709>.
- Florentino M, Xu Z, Smith A, et al. Serial measurement of cell-cycle arrest biomarkers [TIMP-2] - [IGFBP7] and risk for progression to death, dialysis, or severe acute kidney injury in patients with septic shock. *Am J Respir Crit Care Med.* 2020;202:1262-70. <https://doi.org/10.1164/rccm.201906-1197OC>.
- DeMerle KM, Angus DC, Baillie JK, et al. Sepsis subclasses: a framework for development and interpretation. *Crit Care Med.* 2021;49:748-59. <https://doi.org/10.1097/CCM.0000000000004842>.
- Bhatraju PK, Zelnick LR, Katz R, et al. A prediction model for severe AKI in critically ill adults that incorporates clinical and biomarker data. *Clin J Am Soc Nephrol.* 2019;14:506-14. <https://doi.org/10.2215/CJN.04100318>.
- Wiersema R, Jukarainen S, Vaara ST, et al. Two subphenotypes of septic acute kidney injury are associated with different 90-day mortality and renal recovery. *Crit Care.* 2020;24:150. <https://doi.org/10.1186/s13054-020-02866-x>.
- Chaudhary K, Vaid A, Duffy Á, et al. Utilization of deep learning for subphenotype identification in sepsis-associated acute kidney injury. *Clin J Am Soc Nephrol.* 2020;15:1557-65. <https://doi.org/10.2215/CJN.09330 819>.
- Madushani RWMA, Patel V, Loftus T, et al. Early biomarker signatures in surgical sepsis. *J Surg Res.* 2022;277:372-83. <https://doi.org/10.1016/j.jss.2022.04.052>.
- Reddy K, Sinha P, O'Kane CM, et al. Subphenotypes in critical care: translation into clinical practice. *Lancet Respir Med.* 2020;8:631-43. [https://doi.org/10.1016/S2213-2600\(20\)30124-7](https://doi.org/10.1016/S2213-2600(20)30124-7).
- Stanski NL, Wong HR. Prognostic and predictive enrichment in sepsis. *Nat Rev Nephrol.* 2020;16:20-31. <https://doi.org/10.1038/s41581-019-0199-3>.
- Bhatraju PK, Zelnick LR, Herting J, et al. Identification of acute kidney injury subphenotypes with differing molecular signatures and responses to vasopressin therapy. *Am J Respir Crit Care Med.* 2019;199:863-72. <https://doi.org/10.1164/rccm.201807-1346OC>.
- Wick KD, McAuley DF, Levitt JE, et al. Promises and challenges of personalized medicine to guide ARDS therapy. *Crit Care.* 2021;25:404. <https://doi.org/10.1186/s13054-021-03822-z>.
- Sinha P, Kerchberger VE, Willmore A, et al. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. *Lancet Respir Med.* 2023;11:965-74. [https://doi.org/10.1016/S2213-2600\(23\)00237-0](https://doi.org/10.1016/S2213-2600(23)00237-0).

29. Seymour CW, Kennedy JN, Wang S, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. *JAMA*. 2019;321:2003–17. <https://doi.org/10.1001/jama.2019.5791>.
30. Dellinger RP, Bagshaw SM, Antonelli M, et al. Effect of targeted polymyxin b hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. *JAMA*. 2018;320:1455–63. <https://doi.org/10.1001/jama.2018.14618>.
31. Klein DJ, Foster D, Walker PM, et al. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. *Intensive Care Med*. 2018;44:2205–12. <https://doi.org/10.1007/s00134-018-5463-7>.
32. Tomlinson G, Al-Khafaji A, Conrad SA, et al. Bayesian methods: a potential path forward for sepsis trials. *Crit Care*. 2023;27:432. <https://doi.org/10.1186/s13054-023-04717-x>.
33. Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. *N Engl J Med*. 2017;377:419–30. <https://doi.org/10.1056/NEJMoa1704154>.
34. Wieruszewski PM, Bellomo R, Busse LW, et al. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial. *Crit Care*. 2023;27:175. <https://doi.org/10.1186/s13054-023-04446-1>.
35. Tumlin JA, Murugan R, Deane AM, et al. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. *Crit Care Med*. 2018;46:949–57. <https://doi.org/10.1097/CCM.0000000000003092>.
36. Bellomo R, Wunderink RG, Szerlip H, et al. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. *Crit Care*. 2020;24:43. <https://doi.org/10.1186/s13054-020-2733-x>.
37. Bellomo R, Forni LG, Busse LW, et al. Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock: a clinical trial. *Am J Respir Crit Care Med*. 2020;202:1253–61. <https://doi.org/10.1164/rccm.201911-2172OC>.
38. Legrand M, Bokoch MP. The Yin and Yang of the renin-angiotensin-aldosterone system in AKI. *Am J Respir Crit Care Med*. 2020. <https://doi.org/10.1164/rccm.202012-4419ED>.
39. Ostermann M, Boldt DW, Harper MD, et al. Angiotensin in ECMO patients with refractory shock. *Crit Care*. 2018;22:288. <https://doi.org/10.1186/s13054-018-2225-4>.
40. Gleeson PJ, Crippa IA, Mongkolpun W, et al. Renin as a marker of tissue-perfusion and prognosis in critically ill patients. *Crit Care Med*. 2019;47:152–8. <https://doi.org/10.1097/CCM.0000000000003544>.
41. Jeyaraju M, McCurdy MT, Levine AR, et al. Renin kinetics are superior to lactate kinetics for predicting in-hospital mortality in hypotensive critically ill patients. *Crit Care Med*. 2022;50:50–60. <https://doi.org/10.1097/CCM.0000000000005143>.
42. RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, et al. Intensity of continuous renal-replacement therapy in critically ill patients. *N Engl J Med*. 2009;361:1627–38. <https://doi.org/10.1056/NEJMoa0902413>.
43. Legrand M, Bagshaw SM, Koyner JL, et al. Optimizing the design and analysis of future AKI trials. *J Am Soc Nephrol*. 2022;33:1459–70. <https://doi.org/10.1681/ASN.2021121605>.
44. Pickkers P, Mehta RL, Murray PT, et al. Effect of human recombinant alkaline phosphatase on 7-day creatinine clearance in patients with sepsis-associated acute kidney injury: a randomized clinical trial. *JAMA*. 2018;320:1998–2009. <https://doi.org/10.1001/jama.2018.14283>.
45. Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated. ... *BMJ Open*. <https://bmjopen.bmj.com/content/13/4/e065613>. Accessed 9 May 2023
46. Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL) *Intensive Care Medicine*. <https://doi.org/10.1007/s00134-023-07271-w>. Accessed 3 Mar 2024
47. Rubin EB, Buehler AE, Halpern SD. States worse than death among hospitalized patients with serious illnesses. *JAMA Intern Med*. 2016;176:1557–9. <https://doi.org/10.1001/jamainternmed.2016.4362>.
48. Atramont A, Lindecker-Cournil V, Rudant J, et al. Association of age with short-term and long-term mortality among patients discharged from intensive care units in France. *JAMA Netw Open*. 2019;2:e193215. <https://doi.org/10.1001/jamanetworkopen.2019.3215>.
49. Martin GL, Atramont A, Mazars M, et al. Days spent at home and mortality after critical illness: a cluster analysis using nationwide data. *Chest*. 2023;163:826–42. <https://doi.org/10.1016/j.chest.2022.10.008>.
50. Villeneuve P-M, Clark EG, Sikora L, et al. Health-related quality-of-life among survivors of acute kidney injury in the intensive care unit: a systematic review. *Intensive Care Med*. 2016;42:137–46. <https://doi.org/10.1007/s00134-015-4151-0>.
51. Auriemma CL, O'Donnell H, Jones J, et al. Patient perspectives on states worse than death: a qualitative study with implications for patient-centered outcomes and values elicitation. *Palliat Med*. 2022;36:348–57. <https://doi.org/10.1177/02692163211058596>.
52. Dinglas VD, Cherukuri SPS, Needham DM. Core outcomes sets for studies evaluating critical illness and patient recovery. *Curr Opin Crit Care*. 2020;26:489–99. <https://doi.org/10.1097/MCC.0000000000000750>.
53. Andersen SK, Butler RA, Chang C-CH, et al. Prevalence of long-term decision regret and associated risk factors in a large cohort of ICU surrogate decision makers. *Crit Care*. 2023;27:61. <https://doi.org/10.1186/s13054-023-04332-w>.
54. Auriemma CL, Harhay MO, Haines KJ, et al. What matters to patients and their families during and after critical illness: a qualitative study. *Am J Crit Care*. 2021;30:11–20. <https://doi.org/10.4037/ajcc2021398>.
55. Hauschildt KE, Seigworth C, Kamphuis LA, et al. Financial toxicity after acute respiratory distress syndrome: a national qualitative cohort study. *Crit Care Med*. 2020;48:1103–10. <https://doi.org/10.1097/CCM.0000000000004378>.
56. Arnup SJ, McKenzie JE, Hemming K, et al. Understanding the cluster randomised crossover design: a graphical illustration of the components of variation and a sample size tutorial. *Trials*. 2017;18:381. <https://doi.org/10.1186/s13063-017-2113-2>.
57. Semler MW, Self WH, Wanderer JP, et al. Balanced crystalloids versus saline in critically ill adults. *N Engl J Med*. 2018;378:829–39. <https://doi.org/10.1056/NEJMoa1711584>.
58. Toporek AH, Semler MW, Self WH, et al. Balanced crystalloids versus saline in critically ill adults with hyperkalemia or acute kidney injury: secondary analysis of a clinical trial. *Am J Respir Crit Care Med*. 2021;203:1322–5. <https://doi.org/10.1164/rccm.202011-4122LE>.
59. I-SPY COVID Consortium. Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial. *EClinicalMedicine*. 2023;58:101889. <https://doi.org/10.1016/j.eclinm.2023.101889>.
60. Kent DM, Paulus JK, van Klaveren D, et al. The predictive approaches to treatment effect heterogeneity (PATH) statement. *Ann Intern Med*. 2020;172:35–45. <https://doi.org/10.7326/M18-3667>.
61. Writing Committee for the REMAP-CAP Investigators, Lawler PR, Derde LPG, et al. Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19: a randomized clinical trial. *JAMA*. 2023;329:1183–96. <https://doi.org/10.1001/jama.2023.4480>.
62. Zampieri FG, Damiani LP, Bagshaw SM, et al. Conditional treatment effect analysis of two infusion rates for fluid challenges in critically ill patients: a secondary analysis of balanced solution versus saline in intensive care study (BaSICS) trial. *Ann Am Thorac Soc*. 2023. <https://doi.org/10.1513/AnnalsATS.202211-946OC>.
63. Seitz KP, Spicer AB, Casey JD, et al. Individualized treatment effects of bougie vs stylet for tracheal intubation in critical illness. *Am J Respir Crit Care Med*. 2023. <https://doi.org/10.1164/rccm.202209-1799OC>.
64. Seymour CW, Gomez H, Chang C-CH, et al. Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness. *Crit Care*. 2017;21:257. <https://doi.org/10.1186/s13054-017-1836-5>.
65. Stanski NL, Rodrigues CE, Strader M, et al. Precision management of acute kidney injury in the intensive care unit: current state of the art. *Intensive Care Med*. 2023;49:1049–61. <https://doi.org/10.1007/s00134-023-07171-z>.
66. Ham KR, Boldt DW, McCurdy MT, et al. Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial. *Ann Intensive Care*. 2019;9:63. <https://doi.org/10.1186/s13613-019-0536-5>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.